[Targeted therapy: toward a clean and effective war against cancer].
One promising avenue towards the development of more selective, better anticancer drugs consists in the targeted delivery of bioactive compounds to the tumor environment by means of binding molecules specific for tumor-associated biomarkers. Eligibility of such markers for therapeutic use implies ideally three criteria : (i) accessibility from the bloodstream, (ii) expression at sufficient level and (iii) no (or much lower) expression in normal tissues. Most current discovery strategies (such as biomarker searching into body fluids) provide no clue as to whether proteins of interest are accessible, in human tissues, to suitable high-affinity ligands, such as systemically delivered monoclonal antibodies. Innovative proteomic technologies are able to identify such accessible biomarkers and represent a key step in the clinical development of such target therapies.
Castronovo
V
V
Laboratoire de Recherche sur les Metastases (GIGA-Cancer), Université de Liège, Liège, Belgique.
Waltregny
D
D
Detry
O
O
Coimbra Marques
C
C
De Roover
A
A
Honoré
P
P
De Pauw
E
E
Turtoi
A
A
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D014408:Biomarkers, Tumor / Q000378:metabolism; D016503:Drug Delivery Systems; D006801:Humans; D009369:Neoplasms / Q000378:metabolism / Q000628:therapy*; D040901:Proteomics
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor